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Abstract 
The LIG superfamily is characterized by its unique extracellular domain structure 
which contains a series of leucine-rich repeats (LRRs) followed by one or more 
Immunoglobulin (Ig) domains. Knowledge about biological pathways regulated by LIG 
family members is still at its infancy, though some members have been associated with 
novel biological functions such as inhibition of epidermal growth factor receptor (EGFR) 
in Drosophila and neuronal regeneration in humans. The goal of this project was: to 
design a high-throughput protein interaction assay to rapidly identify potential binding 
partners for LIG family members that may provide insight to their biological function.  
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Background 
 Cell-to-cell communication is critical for the survival and development of 
multicellular organisms. Development from a fertilized egg to a complete organism 
requires communication and interaction among billions of cells. Research in the area of 
cell signaling have helped provide some answers to the most important questions in 
biology, such as how cell fates are determined and how different types of cancer 
progress. Work in the Duffy lab has been involved in investigating cell-to-cell 
communication. One of the most important findings discovered by the lab is the function 
of the Drosophila transmembrane molecule Kekkon 1 (Kek1) in a negative feedback loop 
to regulate the activity of the Epidermal Growth Factor Receptor (EGFR) during 
oogenesis (Ghiglione et al., 1999).   
Overview of Epidermal Growth Factor Receptor (EGFR) Family 
 EGFR or ErbB is the first cell-surface receptor to be linked directly to cancer. 
Following the identification of EGFR in humans, three additional members of the 
receptor family were discovered including ErbB2, ErbB3, and ErbB4. The general 
structure of EGFR and other family members consists of a heavily glycosylated 
extracellular region with 4 domains (I-IV), a transmembrane domain, and cytoplasmic 
tyrosine kinase domain (Figure 1) (Burgess et al., 2003).  
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Figure 1: Domain Organization of Epidermal Growth Factor Receptor (Burgess et 
al., 2003) 
Ligand binding to the extracellular domain of EGFR via contacts in domain I and 
III locks the receptor in an active conformation and exposes the dimerization arm in 
domain II. Subsequent receptor homo- or hetero- dimerization triggers 
transphosphorylation of a specific subset of tyrosine residues in the C-terminal tail 
(Figure 2). A variety of cytoplasmic kinase cascades, such as mitogen-activated protein 
kinase (MAPK), can follow (Schlessinger, 2002).         
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Distinct among four human ErbB receptors, ErbB2 has no known soluble ligand to 
control its activity. Its structure reveals domain II in an “inactive” conformation and 
direct interactions between domain I and III in the extracellular region, which keep the 
receptor in open conformation and prevent ligands from binding (Burgess et al., 2003). 
Due to its open configuration, ErbB2 is regarded as an ‘auto-activated receptor’ that can 
transform cells and cause cancer simply through overexpression. Sequence analyses show 
similarity in sequence and overall domain arrangement between the single EGFR family 
member present in D. melanogaster - dEGFR/DER and human EGFR family members. 
For example, ErbB2 and dEGFR share 35% sequence identity over domains I-IV 
(Alvarado et al., 2009). The one major exception to the structural and sequence similarity 
is in the presence of an extra domain, termed domain V, in the extracellular region of the 
Figure 2: Mechanism of Activation of Epidermal Growth Factor Receptor  
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Drosophila receptor.  Morever, recent structural studies on dEGFR revealed that even 
though its activity is ligand dependent like the EGFR, its structure is actually more 
closely related to that of ErbB2. This surprising result indicating that the Drosophila 
receptor is in an open configuration suggests that the Drosophila receptor may require 
additional levels of regulation to ensure activity remains ligand dependent. 
 
Kek1/dEGFR Interaction  
 As mentioned above, dEGFR is the ErbB2 homolog in Drosophila. The receptor’s 
activity, regulated by both stimulatory and inhibitory molecules, plays a key role in many 
developmental decisions such as dorsal-ventral polarity, segmental identity, cuticle 
production and cell growth. Kekkon 1or Kek1, a Drosophila transmembrane molecule, 
can form a complex with dEGFR and inhibits this tyrosine kinase pathway in multiple 
tissues.  Kek1 is the founding member of the Kekkon family, a set of six transmembrane 
proteins in Drosophila and a sub-division of LIG superfamily. LIG proteins’ extracellular 
regions are characterized by leucine-rich repeats (LRR), an amino (N) and carboxyl (C) 
cysteine rich region flanking the LRRs, and a C2-like immunoglobulin (Ig) domain 
(Figure 3). 
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Figure 3: Schematic structures of LIG family members in Drosophila 
 
Kek1 null mutations are associated with an increase in dEGFR signaling and can 
compensate for a decrease in receptor activity during oogenesis (Ghiglione et al., 1999). 
The Kek LRR domain is sufficient for dEGFR binding in vitro, but the 
juxta/transmembrane (jt/tm) portion of the molecule is critical for inhibition in vivo, as 
demonstrated by non-functional secreted forms of Kek1 and domain swaps (Alvarado et 
al., 2004). Domain swaps containing the Kek1 LRRs in a Kek2 backbone are inactive 
even though membrane tethered through the Kek2 transmembrane domain. This suggests 
the LRR-mediated inhibition of dEGFR is a bipartite process: the LRRs direct binding to 
the receptor, while the jt/tm domain ensures inhibition (Figure 4).  
In addition, mutational analyses with the SOK alleles in dEGFR, mutations 
centered in Domain V, impair the receptor’s association with Kek1, suggesting an 
important role for this Domain in mediating regulation by Kek1 (Alvarado et al., 2004). It 
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is interesting to note that Kek1 has been reported to be associated with not only dEGFR 
but also all human ErbBs, although more recent data does not support its ability to bind to 
the human ErbBs  (Ghiglione et al., 2003; J. Duffy, unpublished).    
 
 
 
 
 
 
 
 
 
 
 
 
Within the Kek family, the ability to associate with and block dEGFR’s activity is 
unique to Kekkon 1. Similar inhibitory effects are not witnessed with Kek2, Kek3 Kek4, 
Kek5 and Kek6, other members of the Kek family (Alvarado et al., 2004).  Of these other 
family members functional data is only reported for Kek5, which appears to modulate 
Transforming Growth Factor-β (TGF-β) signaling (Evans et al., 2009). Thus, existing 
data suggest that LIG family members in Drosophila have distinct functions but likely 
affect different modes of intercellular communication.  
 
 
Figure 4: Kekkon 1 inhibits EGFR in a bipartite mechanism 
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LIGS 
Transmembrane molecules with LRRs and Ig domains in the extracellular region 
are not unique within the LIG family of Drosophila. There have been 36 human LIG 
proteins discovered: four LINGO, three NGL, five SALM, three NLRR, three Pal, two 
ISLR, three LRIG, two GPR, two Adlican, two Peroxidasin-like proteins, three Trk 
neurotrophin receptors, a yet unnamed protein AAI11068, and three AMIGO (Homma et 
al., 2008). The structures of LIG superfamily members are represented in Figure 5. 
Though their functions are possibly diverse, some LIG proteins have been shown to 
contribute in neuronal function and development. While neuronal activity may be a 
theme, an understanding of the cellular and CNS functions of the LIG family is still at its 
infancy. Major families of LIG protein (AMIGO, LINGO, NGL, NLRR, and LRIG) 
along with their recently discovered functions are reviewed below.  
13 
 
 
Figure 5: Summary of the structures of LIG superfamily’s members (Homma et al., 
2008) 
     
Amphoterin-induced gene and ORF (AMIGO) Family:  This family is named after a gene 
first found in rat hippocampal neurons. The family is consisted of three members: 
AMIGO-1, AMIGO-2, and AMIGO-3. They share the typical structure of type I 
transmembrane proteins with six LRRs and a single Immunoglobulin-like domain located 
next to the transmembrane region. Studies suggest exclusive expression of AMIGO in the 
nervous system and its significant contribution in hippocampal formation (Chen et al., 
2005). Substrate-bound AMIGO ectodomain has been shown to promote neurite 
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extension of culture hippocampal neurons while the ectodomain itself, when added to the 
medium, restricts fasciculation of neurites. It is important to note that members of the 
AMIGO family demonstrate both homophilic and heterophilic binding activity, 
suggesting their role as novel cell adhesion molecules that monitor neuronal growth 
(Chen et al., 2005).       
 
LRR and Ig domain containing Nogo Receptor interacting protein (LINGO) Family: 
LINGO-1 is the founding member of the LINGO family and was first discovered as the 
missing molecule required for NgR/p75 signaling, which directs inhibition of neuronal 
regeneration in spinal cord and brain injury (Chen et al., 2005). LINGO is a type I 
transmembrane protein with 12 LRRs and an Ig-like domain. LINGO 1 is specifically 
brain-enriched while the other three members of the family, LINGO 2-4, have wider 
distribution. Studies have indicated multiple functions of LINGO-1 in the Central 
Nervous System (CNS). Beside its mandatory role in neurite outgrowth inhibition, 
LINGO-1 contributes in modulating oligodendrocyte differentiation and myelination 
(Chen et al., 2005).  
 
NGL-1: NGL-1 was discovered through interaction screen with Netrin G1, a highly 
conserved axonal guidance cue that monitors precise connections between neurons and 
their targets during development (Chen et al., 2005). NGL-1is exclusively enriched in 
brain and found abundantly in the striatum and the cerebral cortex. NGL-1 and Netrin G1 
function together, playing an important role in the growth of thalamocortical neurons. As 
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a type I transmembrane protein NGL-1 has an extracellular domain containing nine LRRs 
and an Ig-like domain. The exact role of NGL-1 in the CNS remains to be investigated 
(Chen et al., 2005).    
 
Neuronal Leucine-Rich Repeat (NLRR) Family: Four members of NLRR family have 
been identified and named NLRR1-4. All of them were shown to be expressed in brain; 
NLRR-2 and NLRR-3 are exclusively brain-enriched (Chen et al., 2005). The first three 
members of the mammalian NLRR are type I transmembrane protein with an 
extracellular domain consisted of 11-12 LRR repeats, an Ig-like domain, and a FN-III 
domain; NLRR-4 is unique within the family due to its lack of the Ig-like domain. The 
specific cellular and CNS functions of the NLRRs are still under investigation but they 
appear play an important role in neuronal function and development. NLRR-3 has been 
shown to be upregulated during cortical injury; NLRR-3 expression is involved in MAPK 
pathways signaling and is induced by EGF signaling. NLRR-4, on the other hand, plays a 
role in hippocampal dependent memory retention (Chen et al., 2005).          
 
Leucine Rich Repeats and Immunoglobulin-like Domain (LRIG) Family: The LRIG 
family includes three members, LRIG-1, LRIG-2, and LRIG-3, whose structures consist 
of 15 LRRs and 3 Ig-like domains. LRIG-1 and LRIG-2 are expressed in various tissues, 
while LRIG-3 is principally expressed in non-neuronal tissues and in several exceptional 
sites within the nervous system (Homma et al., 2008). It has been suggested that LRIG is 
a regulator of stem cell quiescence, possibly through regulation of EGFR activity; LRIG-
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1 maintains epidermal stem cells in a quiescent non-dividing state and a decrease in 
LRIG-1 expression may trigger proliferation (Jensen and Watt, 2006). 
Epidermal Growth Factor Receptor Family and Cancer  
 Members of EGFR family have been shown to be involved in many types of 
cancer and many studies have illustrated and emphasized the extent and impact of EGFR 
overexpression in a variety of cancer types. EGFR is overexpressed on the cell surface of 
non-small cell lung cancer (NSCLC). Based on the new adenocarcinoma classification 
approved by the International Association for the Study of Lung Cancer, Korean 
researchers identified EGFR mutations in 50.5% of surgically resected lung 
adenocarcinomas in their centers. Use of EGFR tyrosine kinase inhibitors gefitinib and 
erlotinib has showed some effects on patients with adenocarcinomas identified as having 
activating EGFR mutations (Kobayashi et al., 2005).  ErbB2, also a member of EGFR 
family, is amplified in a 20-30% of breast cancers. As such, ErbB2-blocking antibodies 
such as Trastuzumab and Herceptin have been used in combination with chemotherapy in 
treatment of breast cancer (Harari and Yarden, 2000). 
 EGFR overexpression is also often found in prostate cancer, the most frequently 
diagnosed solid tumors in men. EGFR signaling pathway is suggested to help activate 
androgen receptor in androgen-deprived circumstances (Peraldo-Neia et al., 2011). In 
addition, approximately 50-60% of glioblastoma tumors have the EGFR overexpressed; 
the most common EGFR mutant, EGFRvIII, is expressed in 24-67% of cases 
(Heimberger et al., 2005).  Inhibitory molecules and antibodies to EGFR are considered 
the most important drug candidates to target in prostate cancer and glioblastoma. Given 
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this data, the extent and impact of EFGR overexpression have been illustrated and 
emphasized in a variety of cancer types. 
EGFR and LIG interactions 
Given the role of EGFR signaling in cancer biology, the identification of Kek1 and 
LRIG1 as EGFR binding molecules, and the need for novel therapeutics, this project 
aimed to develop a simple and high throughput enzyme-linked-immunosorbent assay 
(ELISA) to screen for interactions between LIG molecules and members of the EGFR 
family, as well as among the LIG proteins themselves. It is expected that the assay could 
provide a quick screen to determine potential binding partners for more in-depth 
investigation.    
Materials and Methods  
Gateway Cloning System  
 The Gateway Cloning system allows DNA constructs to be cloned into a variety of 
vectors without acquiring the use of restriction enzyme. The technology is based 
primarily on the bacteriophage lambda site-specific recombination pathway. The gene of 
interest is integrated into the vectors at specific recombination sites called the att sites. 
The desired plasmids are obtained through BP and LR reactions, both of which are 
mediated by a mix of clonase system. The BP reaction directs recombination between a 
gene of interest flanked by two attB sites and a donor vector containing a ccdB gene 
flanked by two attP sites to produce an entry clone with the DNA fragment of interest 
flanked by two attL sites (B + P  L). The LR reaction then performs recombination 
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between the attL sites the donor vector and the attR sites of the destination vector to 
obtain the final expression clone with the gene of interest flanked by attB sites (L+R  
B) Kanamycin and ampicillin resistance genes in the Gateway vectors, along with 
inclusion of a ccdB gene (toxic to E. coli) into the empty entry and destination vectors, 
provide important restrictions for successful selection of positive clones (Invitrogen, 
2009).         
 Putative secreted Amigo1 (sA1) entry clones previously generated in the Duffy lab 
were used in an LR reaction with a pUAST-6XHIS/V5 destination vector to create an 
expression clone: 7μL pENTR sA1, 1μL of 150ng/μL pUAST-6XHIS/V5 and 2μL LR 
Clonase mix were incubated overnight. 5μL of the LR reaction were transformed into 
DH5α Max Cloning Efficiency cells and plated on LB agar plates containing 50μg/mL 
ampicillin. Colonies were grown overnight in small liquid LB cultures containing 
ampicillin and were then miniprepped using Qiagen’s Qiaprep Spin Miniprep Kit. The 
sA1-6XHIS/V5 clones, along with previously generated constructs sLingo1-6XHIS/V5, 
sLingo1-GFP, sAmigo1-GFP, sAmigo2-6XHIS/V5, sAmigo3-6XHIS/V5, and sAmigo3-
GFP, were midiprepped with Qiagen’s Plasmid Midi Kit. The DNA constructs were then 
sent to sequencing at GENEWIZ, Inc. (Boston, MA) and the resulting chromatograms 
were analyzed using the Sequencher software. DNA concentrations were determined 
using NanoDrop Spectrophotometer.   
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Co-transfection  
An S3 Drosophila cell line was maintained using Schneider’s media with 12.5% 
FBS. Cells were seeded in a 6-well plate at 5x10
6
 cells/well in 2mL of media and 
transfected when the cells were 80-100% confluent using a Qiagen Effectene 
Transfection Kit. sDER-6XHIS/V5, sDER-GFP, sKEK1-6XHIS/V5, sKEK1-GFP, 
sKEK2-6XHIS/V5, sKEK2-GFP, sLINGO1-6XHIS/V5, sLINGO1-GFP, sAMIGO1-
6XHIS/V5, sAMIGO1-GFP, sAMIGO2-6XHIS/V5, sAMIGO2-GFP, sAMIGO3-
6XHIS/V5, sAMIGO3-GFP and ArmGAL4 (driver) were co-transfected into each seeded 
well, for a total of 800ng of DNA. The supernatants were harvested after one week and 
collected in Eppendorf tubes after running through a 22 um Whatman syringe filter.  
Western Blots 
Samples were run in the same pattern on two 8% SDS‐PAGE gels, according to 
the protocol adapted by M. Arata and C. Ernst for the Duffy Lab. Proteins were 
transferred onto nitrocellulose membranes. One membrane was probed with polyclonal 
rabbit anti‐GFP antibody diluted 1: 2000 with 5% NFDM in TBST, while the other was 
probed with monoclonal mouse anti‐6XHIS/V5 antibody diluted 1:5000 with 5% NFDM 
in TBST. Goat‐anti‐mouse secondary antibody was subsequently used for membrane 
probed with monoclonal mouse anti‐6XHIS/V5 antibody while goat-anti-rabbit 
secondary antibody was applied for membrane probed with polyclonal rabbit anti‐GFP 
antibody. Both secondary antibodies were diluted 1:20,000 with 5% NFDM in TBST. 
The detection substrate used was a 1:1 peroxide: luminal solution, and blots were 
developed using an X‐omat and Kodak film. 
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Quantification of 6XHis6XHIS/V5-tagged proteins 
200 µl of 6XHIS/V5-tagged proteins in PBS/BSA were prepared at different 
concentrations, added to the wells of Qiagen Ni-NTA HisSorb Plates and incubated for 1 
hour at room temperature. The wells were washed 3 times, 5 minutes/wash with PBS-
Tween. After the PBS-Tween was removed and the wells were dry, 200 µl of primary 
monoclonal anti-6XHIS/V5 (diluted at 1: 5000 in PBS/BSA) was added and the plate was 
incubated overnight at 4°C. The next day the wells were washed 4 times, 10 
minutes/wash with PBS-Tween. After the final wash, 200 µl of Goat‐anti‐mouse 
secondary antibody (diluted at 1: 20,000 in PBS/BSA) was added to each well and the 
plate was incubated at room temperature for 45-60 minutes. The final washes were 
performed 3 times-10 minute/wash before 200 µl of substrate solution TMB was added 
into the plate. Color development was monitored in a microplate reader at the wavelength 
of 650 nm.  
Results 
Generation of Secreted Isoforms  
Cloning 
  Plasmids DNA of the following constructs were successfully transformed into E. 
coli cells, grown in liquid LB culture, and midi-prepped: sAMIGO1-GFP, sAMIGO2-
6XHIS/V5, sLINGO1-6XHIS/V5, and sLINGO2-GFP. In contrast, growth was not 
observed on the plate and liquid cultures of E. coli cells transformed with sAMIGO1-
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6XHIS/V5 and sAMIGO2-GFP constructs. So LR reactions (Figure 6) were attempted 
from pENTR sAMIGO1 and pUAST-6XHIS/V5 and pENTR sAMIGO2 and pUAST-
GFP in order to generate new sAMIGO1-6XHIS/V5 and sAMIGO2-GFP constructs. 
  
Figure 6: Gateway Cloning System (Invitrogen, 2009) 
 E. coli cells transformed with new sAMIGO1-6XHIS/V5 construct grew on Amp
r
 
plates and in liquid culture, but colonies were not observed with cells transformed with 
new sAMIGO2-GFP construct despite multiple attempts. In total five constructs were 
purified and sent for sequencing for confirmation, sAMIGO1-6XHIS/V5, sAMIGO1-
GFP, sAMIGO2-6XHIS/V5, sLINGO1-6XHIS/V5, and sLINGO2-GFP. 
Sequence verification of Constructs 
 The sequencing results of the generated isoforms constructs were imported into 
Sequencher and contigs generated and experimental sequence was compared with the 
known sequence for each gene (Figure 7). 
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The sequencing results were summarized in Table 1. The identities of the following 
constructs were verified: sLINGO1-6XHIS/V5, sAMIGO1-6XHIS/V5, sAMIGO2-
6XHIS/V5, sAMIGO3-6XHIS/V5, and sAMIGO3-GFP. 
  
Figure 7: Contig Generation and Comparison between the Experimental and Experimental 
Sequences using Sequencer 
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Table 1: Verification of LIG plasmid DNA sequence by Sequencer Software  
Sample Identity Note Verified Construct 
sLINGO1-
6XHIS/V5 
Point mutation at 5’ polylinker region Yes 
sLINGO1-GFP No priming due to low DNA 
concentration 
No 
sAMIGO1-
6XHIS/V5 
One missing nucleotide at 5’ polylinker 
region 
Yes 
sAMIGO1-GFP One insertion right after the start codon No 
sAMIGO2-
6XHIS/V5 
100% consistent with the theoretical 
sequence 
Yes 
sAMIGO3-
6XHIS/V5 
One missing nucleotide at 5’ polylinker 
region and one silent mutation in the 
coding region (GAA observed instead 
of GAG but both coded for Glutamic 
Acid) 
Yes 
sAMIGO3-GFP Point mutation in polylinker region, 
5’AttB site, 3’AttB site, and silent 
mutation in the coding region (GAA 
instead of GAG but both coded for 
Glutamic Acid) 
Yes 
 
 It should be noted from Table 1 that sAMIGO1-GFP construct could not be used 
for protein expression due to the insertion of an additional nucleotide right after the start 
codon followed by severe frameshift mutation. The construct sLINGO1-GFP could not 
be sequenced due to “No priming” error which could possibly be attributed to poor 
quality of the DNA template or low DNA concentration. Though mutations were also 
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reported in the other constructs shown in Table 1, they do not result in translation of 
erroneous protein sequences; therefore, sLINGO1-6XHIS/V5, sAMIGO1-6XHIS/V5, 
sAMIGO2-6XHIS/V5, sAMIGO3-6XHIS/V5, and sAMIGO3-GFP could be used for 
protein expression.   Together with the isoforms of sKEK1-6XHIS/V5, sKEK1-GFP,  
 sKEK2-6XHIS/V5, sKEK2-GFP, sdEGFR-6XHIS/V5, and sdEGFR-GFP, which were 
previously generated and verified in the lab, a total of 11 clones of secreted isoforms of  
 LIG proteins and dEGFR (Table 2) were prepared. 
Table 2: Summary of Secreted Tagged Isoforms Verified by Sequencing 
 
 
 
 
 
 
 
 
 
 
Protein Expression, Verification and Quantification 
 To determine if constructs were able to produce the predicted secreted molecules 
the Drosophila GAL4/UAS cell culture expression system was used (Klueg et al., 2002).  
Construct DNA concentration (ug/ul) 
sdEGFR-6XHIS/V5 3.2 
sKEK1-6XHIS/V5 2.8 
sKEK2-6XHIS/V5 2.2 
sLINGO1-6XHIS/V5 0.8 
sAMIGO1-6XHIS/V5 1.15 
sAMIGO2-6XHIS/V5 1.36 
sAMIGO3-6XHIS/V5 1.26 
sdEGFR-GFP 2.8 
sKek1-GFP 5.3 
sKek2-GFP 1.3 
sAMIGO3-GFP 1.5 
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sd
In this system both the expression clone (e.g. sdEGFR-GFP) and the inducer clone 
(ArmGAL4) were co-transfected into Drosophila S3 cells (Figure 8).  
 
 
 
 
 
 
 
Western Blot Verification for GFP-tagged Proteins  
 After one week of transfection, supernatants were collected, separated from the 
cells, and probed for secreted proteins by Western Blot. The GFP-tagged proteins were 
probed with αGFP antibody is shown in Figure 9.  
 
 
 
 
 
 
 
 
 
Figure 9: Western Blot Verification of EGFP-tagged proteins 
Figure 8: Drosophila cell expression 
system 
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 For sdEGFR-GFP, sKEK1-GFP, sKEK2-GFP, and sAMIGO3-GFP single bands 
were detected at approximately the correct sizes. The theoretical sizes and experimental 
sizes of the EGFP-tagged proteins were compared in Table 3.       
Table 3: Comparison between theoretical and experimental sizes GFP-tagged 
protein 
GFP-tagged Protein Theoretical Protein Size (kDa) Experimentally Determined 
Protein Size (kDa) 
sdEGFR-GFP 126.91 130 
sKEK1-GFP 78.82 93 
sKEK2-GFP 72.35 80 
sAMIGO3-GFP 71.35 75 
 Based on the presence of major single bands for each protein (Figure 9) and their 
relative sizes, secreted versions of sdEGFR-GFP, sKEK1-GFP, sKEK2-GFP, and 
sAMIGO3-GFP are produced and appear stable using this system.  
Western Blot and ELISA Verification for 6XHIS/V5-tagged Proteins  
 As done for the GFP tagged secreted molecules, the expression of 6XHIS/V5-
tagged proteins was also assessed.  In this case they could be verified both by Western 
blot and ELISA due to the ability of the 6XHIS tag to bind to a Ni-NTA-coated surface 
(Figure 10). 
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Figure 10: Western Blot and ELISA Verification of 6XHisV5-Tagged Proteins 
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5% 6XHisV5-Tagged Proteins in PBS/BSA 
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 The Western blot and ELISA results were mostly consistent. The presence of the 
protein on the blot as represented by a band generally corresponded to the high A680 
readings in the ELISA assay as demonstrated in cases of sAMIGO1-6XHIS/V5, 
sAMIGO2-6XHIS/V5, sAMIGO3-6XHIS/V5, sdEGFR-6XHIS/V5, and sKEK1-
6XHIS/V5. In contrast, sLINGO1-6XHIS/V5 was not detected by the Western blot and 
its optical density reading from ELISA was relatively low. It should be noted that the 
cloning and protein expression for sLINGO1 constructs, tagged with either 6XHIS/V5 or 
GFP, met with no real success. The sLINGO1-GFP plasmid constructs could not be 
cloned properly, while sLINGO1-6XHIS/V5 gave no expression even its sequence 
appears correct. The only discrepancy in comparison between the Western and ELISA 
assays was sKEK2-6XHIS/V5, which gave band on the Western blot, but low absorbance 
reading with ELISA. Many factors could explain the difference: the difference in 
sensitivity of the two assays, lack of standard for a baseline in ELISA, or the mistaken 
sample loading. Theoretical and experimental sizes of the 6XHis-tagged proteins were 
compared in Table 4.  
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Table 4: Comparison between theoretical and experimental sizes of 
6XHIS/V5-tagged proteins. 
 
6XHIS/V5-tagged Protein Theoretical Protein 
Size (kDa) 
Experimentally 
Determined 
Protein Size 
(kDa) 
sAMIGO1-6XHIS/V5 45.87 50 
sAMIGO2-6XHIS/V5 48.47 53 
sAMIGO3-6XHIS/V5 45.92 48 
sdEGFR-6XHIS/V5 52.81 56 
sKEK1-6XHIS/V5 46.59 48 
sKEK2-6XHIS/V5 100.9 120 
  
Table 4 demonstrated that the difference between theoretical and experimentally 
determined size of 6XHIS/V5-tagged secreted proteins were minimal. Size verification 
on Table 4 and Western Blot and ELISA shown in Figure 10 supported the presence of 
sAMIGO1-6XHIS/V5, sAMIGO2-6XHIS/V5, sAMIGO3-6XHIS/V5, sdEGFR-
6XHIS/V5, and sKEK1-6XHIS/V5 in the harvested supernatants.   
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Feasibility of High Throughput ELISA Interaction Assay 
With the knowledge that secreted versions of LIGs and the receptor could be 
generated a preliminary test was run to assess the feasibility of an ELISA based 
interaction assay in a 96 well plate format (Figure 11).  
 
 
 
 
For this, the ability of Kek1 to interact with the dEGFR was assessed relative to 
cell supernatant lacking Kek1 expression (Figure 12).  Although preliminary, a stronger 
signal was detected when dEGFR-expressing supernatant was incubated with Kek1-
expressing supernatant as compared to supernatant from control cells lacking Kek1 
expression.  
 
 
 
  
Figure 8: Schematic Interaction Assay 
Figure 12: ELISA Based Interaction Assay 
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Discussion 
The study indicated that tagged and secreted versions of dEGFR, Kek1, Kek2, and 
Amigo 1-3 have been successfully generated. Discrete bands shown on the Western blots 
(Figure 9 and 10) suggested that full-size proteins of LIG family and dEGFR have been 
produced and not subjected to major degradation or processing steps.  Using the 
Drosophila cell culture expression system appeared to work effectively as it produced 
stable secreted versions of the proteins. The only exception was LINGO1 constructs for 
which I was unable to generate the GFP tagged clone or demonstrable expression of the 
6XHIS/V5 tagged protein by Western Blot.  As the sequence of LINGO1-6XHIS/V5 was 
wild type, it will be important to clarify if lack of expression of the LINGO1-6XHIS/V5 
was due to poor transfection or lack of protein stability. 
   Initial data also suggested that it was feasible to assess concentrations of tagged 
molecules via ELISA and Fluorescence Spectrometry.  Differences were observed in the 
readings of tagged proteins and negative control. In the next step of the study, a 
standardized approach for quantification of both V5 and GFP-tagged proteins should be 
developed.  Parameters of the plate reader could be better defined to give reproducible 
analyses of levels of GFP tagged molecules. This is critical since it is necessary to define 
the input levels of each protein for the ELISA interaction assay. 
 Primary tests showed the potential of the interaction assay to evaluate the level of 
communication between the members of the LIG superfamily and dEGFR. Testing 
supernatants expressing secreted forms of dEGFR and KEK1 in the ELISA interaction 
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assay resulted in a higher signal than was recorded for the interaction between dEGFR 
and supernatant only. In future studies, the conditions for the ELISA interaction assay, 
such as incubation time and wash time, should be optimized to allow for easy distinction 
between high affinity and low affinity interactions. The development of the assay shows 
great promise as screening test for more in-depth investigations of the LIG proteins and 
their ability to interact with members of the EGFR and other receptor families.   
Ultimately this will open the path for more insight on this superfamily for which little 
functional data exists.  
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